Ovarian masses: imaging and management is a key topic at this years ISUOG World Congress.

Accurate and timely characterisation of ovarian lesions is essential for guiding appropriate clinical management, with ultrasound assessment remaining central to this process. In an era of increasingly sophisticated imaging and evolving terminology, expert ultrasound evaluation continues to play a pivotal role in differentiating benign from malignant adnexal masses.

This dynamic field continues to evolve, supported by updated definitions and clarifications from the International Ovarian Tumor Analysis (IOTA) group, which aim to standardise the sonographic description of adnexal tumors. Congress sessions will explore the application of pattern recognition in distinguishing benign from malignant masses, the emerging role of artificial intelligence in refining these assessments, and the characteristic ultrasound patterns associated with the principal malignant ovarian tumor groups. International experts in the field will debate how collective imaging features inform standardised risk-prediction models, and which ultrasound markers are associated with non-resectable disease and their implications for preoperative planning.

Amid these developments of advancing evidence and ongoing debate, the 36th ISUOG World Congress in London offers a unique opportunity to engage with cutting-edge research and hear directly from international experts in gynecologic ultrasound imaging and gynecologic oncology. Through scientific sessions and expert-led discussions spanning global perspectives, attendees will deepen their understanding of ovarian lesion assessment, refine their diagnostic approach and explore the controversies shaping contemporary practice.
 

Why are ovarian masses a key topic at ISUOG 2026?

Ovarian masses remain one of the key topics at the ISUOG Congress, and this year, important new findings and management strategies will be presented and discussed. Sessions will address the safety of expectant management, including five-year results from the IOTA 5 study, alongside practical insights into less common ovarian masses through illustrative clinical cases. The programme will also cover what clinicians need to know about mature cystic teratomas—one of the most common ovarian masses- as well as the management of borderline tumors. In addition, the latest consensus statement on IOTA terminology will be presented, highlighting the importance of standardised ultrasound reporting in everyday practice. Emerging applications of artificial intelligence and radiomics applied to ultrasound in ovarian masses will also be discussed. This topic is highly relevant, as accurate, non-invasive diagnosis is essential to guide appropriate management and ensure optimal patient outcomes across different populations. The programme will encompass a wide spectrum of patients, including women of reproductive age, postmenopausal women, adolescents, and pregnant women. Looking ahead, advances in updated risk models, together with innovations in artificial intelligence and imaging analysis, are expected to further improve diagnostic precision and support more personalised and evidence-based clinical decision-making.

Francesa Moro Scientific Committee member

Sessions where you can learn more about this topic at ISUOG 2026 World Congress

Tuesday 16 September
8:30 - [MC] Evaluating women with a possible gynecological malignancy
9:15 - [OC] Imaging in oncology
12:30 - [WS] MDT case discussion: using ultrasound to guide the management of oncology patients
15:15 - [MC] Evaluating ovarian pathology
 
Wednesday 17 September
9:15 - [OC] Diagnosis of ovarian masses
10:20 - [OP] Imaging in oncology
11:30 - [WS] An evidence based approach to the classification of ovarian pathology
15:15 - [OP] Diagnosis of ovarian masses

 

 

Supplement your learning before Congress

Recent UOG articles

UOG videos

Lectures

ISUOG Guideline and Consensus Statements

VISUOG

Malignant struma ovarii main pic.JPG

Malignant struma ovarii

Struma ovarii is a rare form of ovarian mature teratoma that contains mostly thyroid tissue. Malignant transformation is uncommon, only about 5% of struma ovarii being malignant. The variable sonographic features of struma ovarii and its rare occurrence makes the sonographic diagnosis very challenging.

Ovarian dysgerminoma main pic.JPG

Ovarian dysgerminoma

Dysgerminomas are malignant ovarian germ-cell tumors. Malignant germ-cell tumors of the ovary occur in young women, 75% being diagnosed in the second and third decades of life. At macroscopic evaluation, ovarian dysgerminomas are characteristically solid and well-encapsulated with an average diameter of 15 cm.

Sertoli cell tumor.png

Sertoli-Leydig cell tumors

Sertoli cell tumors, Sertoli-Leydig cell tumors and Leydig cell tumors are sex cord-stromal tumors, and one of the rarest gynecological malignancies, accounting for 0.5-1 % of ovarian tumors. Sertoli cell tumors and Sertoli-Leydig cell tumors are most common in young patients.

Brenner tumor main pic.jpg

Brenner tumor

Brenner tumors are surface epithelial–stromal tumors of the ovary, which were first described in detail by Fritz Brenner in 1907. Brenner tumors represent 3.2 % of all ovarian tumors. About 99% of them are benign and most patients are postmenopausal. Brenner tumors are usually unilateral.

Bot main pic.jpg 1

Borderline ovarian tumor (BOT)

Borderline ovarian tumors (BOTs) are epithelial tumors with low grade of malignancy.  BOTs account for 10–15% of epithelial ovarian tumors. These tumors occur in younger women, with almost 30% of patients younger than 40 years, and are often diagnosed at an earlier stage than invasive carcinomas.

clear cells carcinoma main pic.png

Clear cells carcinoma

Clear cell carcinoma represents 5–25% of all ovarian carcinomas. Tumors can measure up to 30 cm in diameter. In most cases, the cut surface reveals a thick-walled cyst with papillary projections. The histologic patterns include tubulocystic, papillary and solid. The most representative image on ultrasound is a unilateral mass larger than 10 cm with a solid component.

Endometrioid main pic.png

Endometrioid carcinoma

Endometrioid carcinoma represents 10-15% of ovarian epithelial carcinomas. In 15-20% of cases endometrial carcinoma is diagnosed at the same time. Tumors are solid or cystic with a mass protruding into the lumen. The most common microscopic pattern is characterised by a confluent glandular epithelial proliferation.

Mucinous main pic.jpg

Mucinous carcinoma

Mucinous carcinomas comprise 2–3% of ovarian carcinomas. Most mucinous carcinomas are well differentiated, containing areas of cystadenoma and atypical proliferative tumor mixed with areas of carcinoma. The size and laterality of the tumor can suggest whether it is primary or metastatic in nature.

serous main pic.jpg

Serous carcinoma

Low grade serous carcinoma (LGSC) is a rare disease whereas high grade serous ovarian carcinoma (HGSC) is the most common ovarian malignancy. Non-invasive LGSCs are often bilateral and papillae on the outer surface of the cyst are frequently present. Invasive LGSCs exhibit a papillary growth.

Metastases to the ovary main pic.JPG

Metastases to the ovary

The ovary is a common site of metastases from malignant tumors. Most metastases in the ovaries originate in the gastrointestinal tract or the breast. The distinction between primary and metastatic ovarian neoplasm is of critical importance, since surgical cytoreduction is the treatment of choice for the former.

Patient information 

Ovarian Carcinosarcoma

This leaflet is to help you understand what an ovarian carcinosarcoma is, what tests you need and the implication of being diagnosed are for you, your baby and your family.

Metatasis of the Ovary

This leaflet is to help you understand what Metastases of the Ovary is, what tests you need and the implication of being diagnosed with Metastases of the Ovary for you, your baby and your family.

Metastatic Lesions

This leaflet is to help you understand what Metastatic Lesions are, what causes them, what tests you need and what the implications of being diagnosed with a tumor.

Malignant struma ovarii

This leaflet is to help you understand what Malignant struma ovarii is, how does it happen, what tests you need and what are the long term implications of the diagnosis.

Granulosa cell tumor

This leaflet is to help you understand what Granulosa cell tumor is, how does it happen, what tests you need and what are the long term implications of the diagnosis.

Epithelial ovarian carcinoma

This leaflet is to help you understand what Epithelial ovarian carcinoma is, what tests you need and the implication of being diagnosed with Epithelial ovarian carcinoma for you, your baby and your family.

Borderline Ovarian Tumor

This leaflet is to help you understand what Borderline Ovarian Tumor is, how does it happen, what tests you need and what are the long term implications of the diagnosis.

CME activities

Key questions

Which sonographic features are most useful in distinguishing benign from malignant adnexal masses?

What do the updated IOTA definitions add to the standardised description and reporting of adnexal tumors?

Which ultrasound markers suggest non-resectable disease, and how should these findings inform preoperative planning?

How might emerging artificial intelligence tools refine adnexal mass assessment and improve diagnostic accuracy in gynecologic ultrasound?

Register for the ISUOG World Congress to get answers to these questions. 

Share